NT-proBNP predicts maintenance of sinus rhythm after electrical cardioversion

Thrombosis Research

Volumn 135, Issue 2, 2015, Pages 289-291

  Andersson, Jonas ^a   Rosenqvist, Ma˚rten ^b   Tornvall, Per ^c   Boman, Kurt ^a  

^a Skelleftea Hospital   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVERSION; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NULL HYPOTHESIS; OUTPATIENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SEX RATIO; SINUS RHYTHM; ATRIAL FIBRILLATION; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 84921523028     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.11.014     Document Type: Article

References (23)

1. Norberg J, Bäckström S, Jansson JH, Johansson L. Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data. Clin Epidemiol 2013;5:475-81.
2. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med 2013;274:461-8.
3. VanGelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;23:1834-40.
4. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, et al. Early and comprehensive management of atrial fibrillation: Executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 2009;30(24):2969-77c.
5. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007;17:CD005049.
6. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68.
7. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007;116:99-109.
8. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000;6:92-6.
9. Knudsen CW, Omland T, Clopton P, Westheim A, Wu AH, Duc P, et al. Impact of atrial fibrillation on the diagnostic performance of b-type natriuretic peptide concentration in dyspneic patients: An analysis from the breathing not properly multinational study. J Am Coll Cardiol 2005;46:838-44.
10. Lee SH, Jung JH, Choi SH, Lee N, Park WJ, Oh DJ, et al. Determinants of brain natriuretic peptide levels in patients with lone atrial fibrillation. Circ J 2006;1:100-4.
11. Wozakowska-Kapłon B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol 2004;12:1555-8.
12. Ari H, Binici S, Ari S, Akkaya M, Koca V, Bozat T, et al. The predictive value of plasma brain natriuretic peptide for the recurrence of atrial fibrillation six months after external cardioversion. Turk Kardiyol Dern Ars 2008;36:456-60.
13. Shin DI, Jaekel K, Schley P, Sause A, Müller M, Fueth R, et al. Plasma levels of nt-pro-bnp in patients with atrial fibrillation before and after electrical cardioversion. Z Kardiol 2005;94:795-800.
14. Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Arnesen H, Smith P. Candesartan, nt-probnp and recurrence of atrial fibrillation after electrical cardioversion. Int J Cardiol 2009;131:234-9.
15. Möllmann H, Weber M, Elsässer A, Nef H, Dill T, Rixe J, et al. Nt-probnp predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J 2008;72:921-5.
16. Almroth H, Höglund N, Boman K, Englund A, Jensen S, Kjellman B, et al. Atorvastatin and persistent atrial fibrillation following cardioversion: A randomized placebo-controlled multicentre study. Eur Heart J 2009;30:827-33. http://dx.doi.org/10.1093/eurheartj/ehp006.
17. Roche. Roche diagnostic corporations 11/12/02. 51 o(k) summary. K022516-elecsys probnp; 2002 [Nov 1 9 2002. Introduction].
18. Tang Y, Yang H, Qiu J. Relationship between brain natriuretic peptide and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-analysis. J Int Med Res 2011;39:1618-24.
19. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of b-type natriuretic peptide. Eur Heart J 2006;14:1648-50.
20. Hall C. Nt-probnp: The mechanism behind the marker. J Card Fail 2005(5 Suppl.):81-3.
21. Henry WL, Morganroth J, Pearlman AS, Clark CE, Redwood DR, Itscoitz SB, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976;2:273-9.
22. Janse MJ. Why does atrial fibrillation occur? Eur Heart J 1997;18:C12-8.
23. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;6A:2D-8D.